Skip to main content
Journal cover image

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

Publication ,  Journal Article
Bures, R; Gaitan, A; Zhu, T; Graziosi, C; McGrath, KM; Tartaglia, J; Caudrelier, P; El Habib, R; Klein, M; Lazzarin, A; Stablein, DM; Deers, M ...
Published in: AIDS Res Hum Retroviruses
December 10, 2000

Antibodies generated by candidate HIV-1 vaccines in a phase I clinical trial were assessed for neutralizing activity with a panel of eight well-characterized, genetically diverse clade B primary isolates having an R5 phenotype. The vaccines consisted of one of three different recombinant canarypox vectors expressing membrane-anchored HIV-1(MN)gp120 (ALVAC vCP205, vCP1433, and vCP1452) followed by boosting with a soluble gp160 hybrid consisting of MNgp120 and the majority of gp41 from strain IIIB. Serum samples from a subset of volunteers in each arm of the trial, containing moderate to high titers of neutralizing antibodies to HIV-1 MN, were analyzed. Competition assays with peptides revealed that the majority of neutralizing activity was specific for the MN-V3 loop. Despite MN-specific neutralization titers that sometimes exceeded 1:500, no neutralization of primary isolates was detected and, in some cases, mild infection enhancement was observed. In addition, little or no neutralization of the HIV-1 IIIB heterologous T cell line-adapted strain of virus was detected. These results reinforce the notion that monovalent HIV-1 ENV is a poor immunogen for generating cross-reactive neutralizing antibodies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

AIDS Res Hum Retroviruses

DOI

ISSN

0889-2229

Publication Date

December 10, 2000

Volume

16

Issue

18

Start / End Page

2019 / 2035

Location

United States

Related Subject Headings

  • Virology
  • Vaccines, Synthetic
  • Vaccination
  • Phylogeny
  • Peptides
  • Neutralization Tests
  • Molecular Sequence Data
  • Middle Aged
  • Male
  • Immunization, Secondary
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bures, R., Gaitan, A., Zhu, T., Graziosi, C., McGrath, K. M., Tartaglia, J., … Montefiori, D. C. (2000). Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses, 16(18), 2019–2035. https://doi.org/10.1089/088922200750054756
Bures, R., A. Gaitan, T. Zhu, C. Graziosi, K. M. McGrath, J. Tartaglia, P. Caudrelier, et al. “Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.AIDS Res Hum Retroviruses 16, no. 18 (December 10, 2000): 2019–35. https://doi.org/10.1089/088922200750054756.
Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, Caudrelier P, El Habib R, Klein M, Lazzarin A, Stablein DM, Deers M, Corey L, Greenberg ML, Schwartz DH, Montefiori DC. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2019–2035.
Journal cover image

Published In

AIDS Res Hum Retroviruses

DOI

ISSN

0889-2229

Publication Date

December 10, 2000

Volume

16

Issue

18

Start / End Page

2019 / 2035

Location

United States

Related Subject Headings

  • Virology
  • Vaccines, Synthetic
  • Vaccination
  • Phylogeny
  • Peptides
  • Neutralization Tests
  • Molecular Sequence Data
  • Middle Aged
  • Male
  • Immunization, Secondary